https://orcid.org/0000-0003-3993-1569
Figures & data
Figure 1 LS mean percentage change from baseline in SNOT-22 total score (A), LS mean change from baseline in top 5 important SNOT-22 items: (B) decreased sense of smell/taste, (C) nasal blockage, (D) cough, (E) reduced productivity, and (F) wake up tired, in patients with asthma with comorbid CRS.
Notes: Data are LS mean (±SE). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs placebo.
Abbreviations: BL, baseline; CRS, chronic rhinosinusitis; LS, least squares; q2w, every 2 weeks; SE, standard error; SNOT-22, 22-item Sino-Nasal Outcome Test.
Figure 2 LS mean change from baseline in SNOT-22 domain (nasal, ear/facial, sleep, function, emotion) scores dupilumab vs placebo at Week 52 in patients with asthma with comorbid CRS.
Notes: *p < 0.05, **p < 0.01, ****p < 0.0001 vs placebo.
Abbreviations: CI, confidence interval; CRS, chronic rhinosinusitis; LS, least squares; SNOT-22, 22-item Sino-Nasal Outcome Test.
